Medullary carcinoma of the colon
Prepared with OnCo (onco.cc/prep/colorectal-medullary-carcinoma/). Orientation, not medical advice; your team knows your case.
My details
What I know, what is unclear, changes to discuss
Saved in this browserMy questions
8 on the sheet- 1.What is my exact diagnosis, stage, and grade, and which tests established them?
- 2.Which biomarkers have been tested on my tumour (for example MLH1 and PMS2 loss, Cadherin-17 and SATB2 positive; CK7, CK20 and CDX2 usually negative, Tumour-infiltrating lymphocytes and IDO-1 expression, BRAF V600E), and what were the results?
- 3.Which subtype is my cancer, and does that change the recommended treatment?
- 4.Is germline (inherited) genetic testing recommended for me or my family?
- 5.For my situation (all stages), which of the standard options do you recommend and why?
- 6.Am I a candidate for Pembrolizumab, Nivolumab, and what side effects should I expect?
- 7.Would a second opinion at a high-volume centre change anything, and can you help arrange it?
- 8.What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?
Tests and results to bring
Biomarker results to ask for: MLH1 and PMS2 loss (over 80 percent), Cadherin-17 and SATB2 positive; CK7, CK20 and CDX2 usually negative, Tumour-infiltrating lymphocytes and IDO-1 expression, BRAF V600E (sporadic MSI-high).
Bring copies of scan reports, pathology and blood results, and a list of every medicine and supplement.
The treatments I may be offered
- All stages: Treated as MSI-high colorectal cancer by stage, with checkpoint inhibitors for mismatch-repair deficient disease. (Mismatch-repair deficient (MSI-high) colorectal cancer, Colorectal cancer, Pembrolizumab, Nivolumab)
From the standard of care recorded for this cancer; which apply depends on your stage and biomarkers. Ask which the team recommends and why.